Oruka Therapeutics Inc. (ORKA)

NasdaqGM: ORKA · Real-Time Price · USD

99.44

-2.38 (-2.34%)

At close: Aug 26, 2026, 3:59 PM

100.00

+0.56%

After-hours: 7:41 PM

The price, the headline numbers and the latest news, in one place.

-2.34% (1D)

Bid	71.53
Market Cap	6.58B
Revenue (ttm)	n/a
Net Income (ttm)	-109.69M
	n/a
	-2.04
	n/a
	-35.1
P/B (ttm)	5.46
P/S (ttm)	n/a
Earnings Date	Nov 11, 2026

Ask	126.45
Volume	526,711
Avg. Volume (20D)	1,221,633
Open	101.30
Previous Close	101.82
Day's Range	98.24 - 102.48
52-Week Range	14.61 - 115.52
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ORKA

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 8, 1997

Employees 68

Stock Exchange NasdaqGM

Ticker Symbol ORKA

Website https://orukatx.com

Full Company Profile

Financial Performance

In 2025, Oruka Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's n/a. Earnings were -105.43M, an increase of undefined%.

Financial Statements

Earnings Surprise

Oruka Therapeutics has released their quarterly earnings on Aug 10, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.55 misses estimates by -0.05, with -19.57% YoY decline.

Next Earnings Release

Oruka Therapeutics Inc. is scheduled to release its earnings on Nov 11, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

2 weeks ago · Zacks

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

1 month ago · Barrons.com

HMI Capital Pares Its Stake in AI Company nCino

Plus, other significant moves in holdings of Oruka Therapeutics, Enliven Therapeutics, NN, and Alvotech.

1 month ago · Insider Monkey

H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA...